Overview

Chemotherapy for Patients With Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and toxicity of pemetrexed dosing that is tailored to individual patient tolerance in patients with advanced non-small cell lung cancer (NSCLC).
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Pemetrexed